Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4% 5-fluorouracil pretreatment with daylight photodynamic therapy for actinic keratoses
2021-001586-21Phase 2Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Apr 2021
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of fluorouracil and methyl aminolevulinate in actinic keratosis (AK) (2 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Complete lesion response rate. Started Apr 2021; status: completed.
02
Drugs
fluorouracilmethyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2021-001586-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001586-21.